Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma
The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Treatment with idelalisib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.
Make all applications for initial authority approval to prescribe idelalisib for the treatment of follicular B-cell non-Hodgkin’s lymphoma in writing and either:
All applications for idelalisib must include both a completed:
- authority prescription form
- Refractory follicular B-cell non-Hodgkin’s lymphoma – idelalisib - Initial PBS authority application form (PB198).
Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.
Page last updated: 31 October 2019
This information was printed 11 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/lymphoma-refractory-follicular-b-cell-non-hodgkins-lymphoma. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.